Group 1 - A class action has been filed against NET Power Inc. on behalf of investors who purchased securities between June 9, 2023, and March 7, 2025 [1] - The allegations include that NET Power misled investors about the timeline and costs associated with Project Permian, indicating that the project would be delayed and more expensive than previously stated due to supply chain issues and other challenges [2] - Following the announcement of third quarter 2023 results, NET Power's stock fell over 18% after revealing a 12-month delay in the expected schedule for Project Permian [3] Group 2 - On March 10, 2025, NET Power disclosed that the total installed cost for Project Permian is now estimated to be between $1.7 billion and $2.0 billion, significantly higher than the previous estimate of $1.1 billion, and announced a delay in the project's timeline to no earlier than 2029 [4] - The company reported a decrease in cash and cash equivalents from $580 million to $533 million, primarily due to operating cash outflows and capital expenditures [4] - Following the fourth quarter and full year 2024 results announcement, NET Power's stock price fell over 31% to close at $4.75 per share [4]

Core Viewpoint - A class action lawsuit has been filed against Manhattan Associates, Inc. for allegedly misleading investors about its growth potential and revenue forecasts during a specified period [1][2]. Summary by Sections Allegations - The complaint claims that during the class period, Manhattan Associates provided investors with optimistic information regarding its expected revenue for fiscal year 2025, including confidence in forecasting despite macroeconomic challenges and the growth potential of its professional services [2]. - It is alleged that the company failed to disclose its actual capability to deliver responsible growth targets, suggesting that either the company was not equipped to meet these targets or its services were inadequate [2]. Financial Results and Stock Impact - On January 28, 2024, Manhattan Associates released its financial results for Q4 and the full fiscal year 2024, along with a reduced revenue guidance for fiscal year 2025, attributing this to a shift in professional services work and reduced customization [3]. - Following this announcement, the stock price fell from $295.10 per share on January 28, 2025, to $222.84 per share on January 29, 2025, marking a decline of over 24% [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Manhattan Associates, with a deadline to file as lead plaintiff by April 28, 2025 [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. ...

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired BigBear.ai Holdings, Inc. (NYSE: BBAI) securities between March 31, 2022 and March 25, 2025. BigBear is an artificial intelligence (“AI”)-driven technology solutions company. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating ...

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities that purchased or otherwise acquired Quantum Computing Inc. (NASDAQ: QUBT) securities between March 30, 2020 and January 15, 2025. Quantum Computing (QCI) purportedly uses nonlinear quantum optics to deliver quantum products for high-performance computing applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) ...

Core Viewpoint - The article highlights the strong performance of Howmet Aerospace Inc. (NYSE: HWM.PR) with a reported return of 11.2% and a total return of 12.6% since the last analysis, indicating a positive investment opportunity in the aerospace sector [1]. Group 1: Company Performance - Howmet Aerospace Inc. has shown a strong buy rating, which has resulted in significant returns for investors [1]. - The company is part of a broader analysis focused on the aerospace, defense, and airline industries, which are expected to have substantial growth prospects [1]. Group 2: Analyst Insights - The analysis is conducted by an experienced analyst with a background in aerospace engineering, providing informed insights into the complexities of the industry [1]. - The investing group offers access to data analytics monitors, enhancing the investment decision-making process [1].

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities that purchased or otherwise acquired Ibotta, Inc. (NYSE: IBTA) common stock pursuant and/or traceable to the registration statement and related prospectus issued in connection with Ibotta's April 18, 2024 initial public offering. Ibotta purports to be a technology company that allows consumer packaged goods brands to deliver digital promotions to millions of consu ...

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a “clinical stage global biopharmaceutical company committed to being a leader in the development a ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Kyndryl and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 27, ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Movado Group, Inc. (“Movado” or the “Company”) (NYSE: MOV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Movado and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 11, 2025, ...